PubRank

Jose R Conejo-Garcia

Author PubWeight™ 71.52‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004 22.96
2 Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003 16.62
3 Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012 2.85
4 Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 2009 2.06
5 Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008 1.92
6 In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res 2009 1.67
7 Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res 2012 1.51
8 Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res 2010 1.44
9 PILAR is a novel modulator of human T-cell expansion. Blood 2008 1.33
10 CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget 2010 1.20
11 Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer Res 2007 1.18
12 CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J Immunol 2010 1.15
13 CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res 2009 1.14
14 Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med 2009 1.10
15 Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther 2005 1.10
16 Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle 2013 1.08
17 Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Res 2013 1.06
18 Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer. Adv Exp Med Biol 2007 1.06
19 Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle 2010 1.02
20 Nanomolecular targeting of dendritic cells for ovarian cancer therapy. Future Oncol 2009 0.94
21 Mycobacterium tuberculosis infection induces il12rb1 splicing to generate a novel IL-12Rbeta1 isoform that enhances DC migration. J Exp Med 2010 0.89
22 Mast cells impair the development of protective anti-tumor immunity. Cancer Immunol Immunother 2012 0.88
23 Anti-tumor immunity: myeloid leukocytes control the immune landscape. Cell Immunol 2012 0.84
24 Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. Integr Biol (Camb) 2013 0.84
25 Role of vascular leukocytes in ovarian cancer neovascularization. Adv Exp Med Biol 2008 0.83
26 Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy. Expert Rev Obstet Gynecol 2012 0.82
27 Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles. Oncoimmunology 2012 0.81
28 Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity. Clin Dev Immunol 2010 0.79
29 It never rains but it pours: potential role of butyrophilins in inhibiting anti-tumor immune responses. Cell Cycle 2011 0.79
30 Double agents in the war on cancer: leukocytes govern ovarian cancer progression. Oncotarget 2012 0.78
31 Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer. Front Immunol 2013 0.78
32 Editorial: A clear vision needs some balance. J Leukoc Biol 2012 0.75
33 PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma. Int J Gynecol Pathol 2020 0.75